Investment
Features
FeesSafety
Academy
More
Pluang+

Blackbaud showcases AI startups driving innovation for nonprofits in 2026 Social Good Startup Program.

Market News
18 Sep 2026
PRNewsWire
View Source
Bullish
Blackbaud showcases AI startups driving innovation for nonprofits in 2026 Social Good Startup Program.

Blackbaud hosted its 2026 Social Good Startup Program showcase, featuring AI-powered startups offering solutions to help nonprofits, educational institutions, and socially responsible companies enhance impact. The startups presented innovations in grantmaking, donor intelligence, volunteer engagement, and strategic planning, integrating with Blackbaud's ecosystem. Public voting and a judges' panel will select winners to be announced at bbcon 2026, with winners gaining sponsorship and marketing support for 2027. Since 2020, the program has supported over 95 startups, fostering significant innovation in social impact technology.

Eleven AI-powered startups showcased innovation for social impact in Blackbaud's 2026 Social Good Startup Pitch Competition. For readers following the Technology sector, here is Pluang's market snapshot as of Sep 18, 2026 18:51 WIB: Of 150 priced US tech stocks, 71 rose and 71 fell. Notable movers include BTDR at USD 11.43 with a 1-day change of +1.69% and a typical hold time of 15 days, NOK at USD 10.78 with a 1-day change of +1.60% and a typical hold time of 64 days, and ACN at USD 187.35 with a 1-day change of -1.55% and a typical hold time of 131 days.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
46 minutes ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
1 hour ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
2 hours ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
3 hours ago
Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays lowered its price target for Lennar Corporation to $70 from a higher level, citing a 52% drop in Q3 net earnings to $284 million and an 8.6% revenue decline to $8.05 billion. The homebuilder faces headwinds from rising mortgage rates and wea...

Analyst Insights
Bearish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App